Stay up-to-date with our latest news and company announcements.

May 7, 2024

Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid and Late-Stage Immunology-Focused Clinical Development Programs

Financing led by SR One, NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences, Longitude Capital and other new and existing investors Proceeds to support ongoing mid- to late-stage clinical development programs for Company’s lead I&I product candidate, obexelimab WALTHAM, Mass, May 7, 2024 (GLOBE NEWSWIRE) – Zenas BioPharma, Inc. today…

May 2, 2024

BridgeBio announces the launch of BridgeBio Oncology Therapeutics (BBOT) with a $200M private financing to accelerate the development of its novel precision oncology pipeline

The financing was led by Cormorant Asset Management and co-led by Omega Funds with participation from Deerfield Management, Google Ventures, EcoR1 Capital, Wellington Management, Enavate Sciences, Surveyor Capital (a Citadel company), Aisling Capital, Casdin Capital, and Longwood Fund The $200M Series B financing provides BBOT with runway to achieve significant clinical inflection points over the…

March 6, 2024

Sionna Therapeutics Announces $182 Million Series C Financing to Advance Clinical Development of Novel Small Molecules in Cystic Fibrosis

Company positioned to have four compounds in clinical trials in 2024 including three NBD1 stabilizers and one ICL4 modulator Edd Fleming, M.D., of Enavate Sciences joins company’s Board of Directors Boston, MA, March 6th, 2024 — Sionna Therapeutics, a clinical-stage life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF),…

January 2, 2024

Enavate Sciences Backs Graviton Bioscience in Financing Round to Advance Development of Selective ROCK2 Inhibitors

Enavate Sciences joins Cormorant Asset Management, Pontifax Venture Capital and Ovid Therapeutics in supporting Graviton’s development of ROCK2 inhibitors across multiple indications New York, NY, January 2, 2024 — Graviton Bioscience, a privately held clinical-stage biotechnology company focused on therapies that inhibit Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2) announced completion of financing from Enavate…

December 20, 2023

Sudo Biosciences Raises $116M Series B Financing to Advance Potential Best-in Class TYK2 Therapeutics Programs into the Clinic

Funding to advance potential first- and best-in-class brain-penetrant TYK2 candidate in multiple sclerosis and potential first- and best-in-class topical dermal TYK2 candidate in psoriasis into the clinic. Top-tier life science investor syndicate co-led by Enavate Sciences and TPG, with participation from Sanofi Ventures, Surveyor Capital (a Citadel company), Monograph Capital, Eventide Asset Management and existing…

November 7, 2023

OrsoBio Announces $60M Series A Financing to Advance Metabolic Portfolio for the Treatment of Obesity and Associated Disorders

Co-led by Longitude Capital and Enavate Sciences, with Significant Participation by Existing Investors Samsara BioCapital and NuevaBio MENLO PARK, Calif. – November 7, 2023 – OrsoBio, Inc. (“OrsoBio” or “the Company”), a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced the successful completion of a $60 million Series A financing, bringing the…

October 3, 2023

Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies

Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., to serve as Chairman and CEO $125 million private placement investment completed with leading institutional investors will support cash runway expected to extend into Q1 2026* Expected to submit three investigational new drug applications (INDs) within 18 months Seattle, WA, and Exton, PA October…

June 29, 2023

Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies

The combined company, which will operate as Immunome, will feature a synergistic platform expected to enable the development of best-in-class targeted cancer therapies across multiple modalities Clay B. Siegall, Ph.D., current Morphimmune President & CEO and former co-founder & CEO of Seagen, Inc., to serve as Chairman and CEO of combined company A concurrent $125…

June 8, 2023

Upstream Bio Announces $200M Series B Financing to Advance UPB-101
for Allergic and Inflammatory Diseases

Funds to support future development of UPB-101 in asthma and CRSwNP Financing led by Enavate Sciences and Venrock Healthcare Capital Partners Bain Capital Life Sciences and Wellington Management join the syndicate WALTHAM, Mass. – June 8, 2023 – Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, today announced the completion of…

November 10, 2022

Edd Fleming, M.D., former Senior Partner at McKinsey and Company, joins Enavate Sciences as Executive Vice President, Commercialization

MENLO PARK, Calif., November 10, 2022— Enavate Sciences, a portfolio company of Patient Square Capital, is pleased to announce that H. Edward (Edd) Fleming, Jr, M.D. has joined the firm as Executive Vice President, Commercialization. Dr. Fleming reports to James Boylan, Chief Executive Officer of Enavate Sciences, and will augment Enavate’s capabilities in the origination,…

Page 1 of 2